Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Next Previous
Trial Profile

Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Generalised seizures; Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Eisai Inc

    • Most Recent Events

    • 14 Aug 2023 According to a Catalyst Pharmaceuticals media release, results from this study will be presented at the upcoming 35th International Epilepsy Congress taking place on September 2 - 6, 2023 in Dublin, Ireland
    • 27 Apr 2023 Results assessing change in baseline in cognition scores, efficacy, and safety in a subgroup of patients with a history of psychiatric and behavioral events, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, data from this study (to be presented in AAN 2023) is presented online https://index.mirasmart.com/aan2023/PDFfiles/AAN2023-002293.html.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top